BioWorld

March 2, 2007

$50M Invested In Microbia For Late-Stage Drug Trials

Microbia Inc. raised $50 million in private equity to push product development, with a particular focus on multiple Phase II studies of its two lead products. (BioWorld Today) Read More

EUSA Launches With $175M Financing, OPi Acquisition

New Fly Model Of PolyQ Disease Shows Vicious Instability Loop

Point Shares Fall On Mixed Phase III, Bad Phase II Update

Sirtris Seeks $60M To Advance Sirtuin-Red Wine Connection

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for Dec. 10, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 10, 2025.

Epigenetic technology could eliminate misfolded prion proteins

BioWorld Science

The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Brenig Therapeutics discovers new LRRK2 inhibitors

BioWorld Science

Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...